Schering AG, Germany, Announces European Approval of Radioimmunotherapy Zevalin®
Schering AG, Germany, Announces European Approval of Radioimmunotherapy Zevalin® Media Alert Zevalin® combines the targeting ability of an anti-CD20 monoclonal antibody with the cytotoxic power of beta radiation emitted by the yttrium-90 isotope (Ytracis®) - a pure beta emitter radiopharmaceutical - to effectively destroy lymphoma cells. Radioimmunotherapy with Zevalin® has been shown to be effective in patients who were refractory to antibody treatment thus offering a new prospect for improving the quality of life for these patients. What: Journalists are invited to access live webcast to learn more about this novel treatment When: Monday, January 26, 2003 (1:00 P.M. GMT / 2:00 P.M. CET) PANELISTS: David Guy (Moderator) Vice President, Strategic Marketing & Business Development, Oncology Specialized Therapeutics, Schering AG Group Dr. Anton Hagenbeek University Medical Center Utrecht (UMCU) (The Netherlands) Dr. Tim Illidge University of Southampton School of Medicine (United Kingdom) WHY: NHL is the fifth most common cancer in the world, after breast, prostrate, lung and colon cancer. An estimated 230,000 people are now living with this disease in the European Union, with approximately 70,000 new cases diagnosed each year. The average survival for patients with follicular lymphomas has been estimated between six and ten years. Login information: Pressrelease today at 8.00 URL Address: www.schering.de/scripts/en/50_media/2004/events/040126_webcast.php Instructions: Real Player or Windows Media Player software will be required for the webcast. Help Line: +49-69-75-085-720 Dial-in Numbers for conference call: US Toll Free Dial in number: 800 218 4007 UK - Local Dial in number: +44(0) 208 515 2334 This media alert has been published by Corporate Communications of Schering AG, Berlin, Germany. Schering Nordiska AB är ett dotterbolag till Schering AG, ett forskningsbaserat läkemedelsföretag. Företagets verksamhet är fokuserad på fertilitetskontroll och hormonterapi, diagnostik och radiografiska läkemedel, dermatologi och specialiserad terapi för svåra sjukdomar inom området för centrala nervsystemet, onkologi och hjärta/kärl. I egenskap av en global aktör med innovativa produkter strävar Schering efter en ledande ställning över hela världen. Företagets egna starka forsknings- och utvecklingsresurser tillsammans med stödet från ett globalt nätverk av externa partners står som garanti för nya lovande produkter från Schering. Företaget vill genom sin forskning bidra till framsteg inom det medicinska området i strävan efter förbättrad livskvalitet: Making Medicine Work ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/01/26/20040126BIT20020/wkr0006.pdf